{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:06:16Z","timestamp":1784714776535,"version":"3.55.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chikungunya virus (CHIKV) infection can lead to chronic musculoskeletal complications, including persistent arthritis that resembles autoimmune inflammatory conditions. These symptoms have been reported both in endemic populations and in international travellers, with substantial functional and economic consequences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This systematic review and meta-analysis aimed to assess the efficacy and safety of immunomodulatory therapies in chikungunya-related arthritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic search was conducted in PubMed, Scopus, Cochrane, Web of Science, SciELO and LILACS. Risk of bias was assessed using RoB 2.0 for randomized trials, the Newcastle-Ottawa Scale for observational studies and the Joanna Briggs Institute Checklist for case series. A random-effects meta-analysis was performed due to significant heterogeneity (I2\u2009&amp;gt;\u200997%).<\/jats:p>\n                  <jats:p>Results: Eleven studies comprising 742 patients met the inclusion criteria. Methotrexate (MTX) was the most studied immunomodulator. The meta-analysis showed a mean reduction in disease activity score of 2.67 (95% CI: 1.84\u20133.49, P\u2009&amp;lt;\u20090.001, I2\u2009=\u200997.0%) and a decrease in Visual Analogue Scale pain scores of 4.31 (95% CI: 2.56\u20136.06, P\u2009&amp;lt;\u20090.001, I2\u2009=\u200999.1%). Subgroup analysis suggested greater pain reduction in short-term studies. No severe adverse events were reported, but long-term safety data are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Immunomodulatory therapy, particularly MTX, may provide symptom relief in chikungunya arthritis. These findings are relevant not only for endemic settings but also for travel medicine, as chikungunya-related arthritis has been increasingly reported in travellers. However, high study heterogeneity and the lack of randomized trials limit definitive conclusions. Future research should focus on standardizing outcome measures, biomarker-driven patient selection and long-term safety assessments. Clinicians treating returning travellers with chronic joint symptoms should consider post-CHIKV arthritis as part of the differential diagnosis and be aware of potential treatment options.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taaf067","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T12:12:37Z","timestamp":1752495157000},"source":"Crossref","is-referenced-by-count":8,"title":["Immunomodulatory therapy of chikungunya arthritis: systematic review and meta-analysis"],"prefix":"10.1093","volume":"32","author":[{"given":"Jos\u00e9 Kennedy","family":"Amaral","sequence":"first","affiliation":[{"name":"Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University of Cariri , 284 Divino Salvador Street, 63090-000 Barbalha, Cear\u00e1 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Taylor","family":"Schoen","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Allergy, and Immunology, Yale University School of Medicine , 15 York Street, New Haven, CT 06510 \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton O","family":"Bingham","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine , 5200 Eastern Ave, Baltimore, MD 21224 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medicine, George Washington University , 2150 Pennsylvania Ave Suite 5-416, Washington, DC 20037 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelita Lima","family":"C\u00e2ndido","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University of Cariri , 284 Divino Salvador Street, 63090-000 Barbalha, Cear\u00e1 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2025100302021585300_ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-023-00429-2","article-title":"Chikungunya fever [published correction appears in Nat rev dis primers. 2023 May 19;9(1):26. https:\/\/doi.org\/10.1038\/s41572-023-00442-5]","volume":"9","author":"Bartholomeeusen","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2025100302021585300_ref2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya virus and the global spread of a mosquito-borne disease","volume":"372","author":"Weaver","year":"2015","journal-title":"N Engl J Med"},{"key":"2025100302021585300_ref3","doi-asserted-by":"crossref","first-page":"102603","DOI":"10.1016\/j.tmaid.2023.102603","article-title":"Global geotemporal distribution of chikungunya disease, 2011-2022","volume":"54","author":"Grabenstein","year":"2023","journal-title":"Travel Med Infect Dis"},{"key":"2025100302021585300_ref4","first-page":"100673","article-title":"Chikungunya: a decade of burden in the Americas","volume":"30","author":"Souza","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"2025100302021585300_ref5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1473-3099(23)00810-1","article-title":"Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study [published correction appears in lancet infect dis. 2024;24(5):e281. https:\/\/doi.org\/10.1016\/S1473-3099(24)00256-1]","volume":"24","author":"Kang","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025100302021585300_ref6","doi-asserted-by":"crossref","first-page":"13878","DOI":"10.1128\/JVI.02666-13","article-title":"Chronic joint disease caused by persistent chikungunya virus infection is controlled by the adaptive immune response","volume":"87","author":"Hawman","year":"2013","journal-title":"J Virol"},{"key":"2025100302021585300_ref7","doi-asserted-by":"crossref","first-page":"e1007993","DOI":"10.1371\/journal.ppat.1007993","article-title":"Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA","volume":"15","author":"Young","year":"2019","journal-title":"PLoS Pathog"},{"key":"2025100302021585300_ref8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/qjmed\/hcae028","article-title":"Chronic chikungunya disease (CCD): clinical insights, immunopathogenesis and therapeutic perspectives","volume":"117","author":"Ng","year":"2024","journal-title":"QJM"},{"key":"2025100302021585300_ref9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fcimb.2018.00345","article-title":"Cellular and molecular immune response to chikungunya virus infection","volume":"8","author":"Tanabe","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"2025100302021585300_ref10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/art.40403","article-title":"Chikungunya arthritis: implications of acute and chronic inflammation mechanisms on disease management [published correction appears in arthritis Rheumatol. 2018;70(10):1596. https:\/\/doi.org\/10.1002\/art.40719]","volume":"70","author":"Zaid","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025100302021585300_ref11","doi-asserted-by":"crossref","first-page":"e00404","DOI":"10.1590\/0037-8682-0433-2023","article-title":"Bone erosions and joint damage caused by chikungunya virus: a systematic review","volume":"57","author":"Amaral","year":"2024","journal-title":"Rev Soc Bras Med Trop"},{"key":"2025100302021585300_ref12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/v14020242","article-title":"Current understanding of the role of T cells in chikungunya, dengue and Zika infections","volume":"14","author":"Mapalagamage","year":"2022","journal-title":"Viruses"},{"key":"2025100302021585300_ref13","doi-asserted-by":"crossref","first-page":"e0299521","DOI":"10.1371\/journal.pone.0299521","article-title":"Cytokine and T cell responses in post-chikungunya viral arthritis: a cross-sectional study","volume":"19","author":"Chang","year":"2024","journal-title":"PloS One"},{"key":"2025100302021585300_ref14","doi-asserted-by":"crossref","first-page":"eaal1333","DOI":"10.1126\/scitranslmed.aal1333","article-title":"Fingolimod treatment abrogates chikungunya virus-induced arthralgia","volume":"9","author":"Teo","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025100302021585300_ref15","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1038\/s41598-023-34578-x","article-title":"Effects of rIL2\/anti-IL2 antibody complex on chikungunya virus-induced chronic arthritis in a mouse model","volume":"13","author":"Tritsch","year":"2023","journal-title":"Sci Rep"},{"key":"2025100302021585300_ref16","doi-asserted-by":"crossref","first-page":"101672","DOI":"10.1016\/j.eclinm.2022.101672","article-title":"An evaluation of global chikungunya clinical management guidelines: a systematic review","volume":"54","author":"Webb","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025100302021585300_ref17","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.microb.2023.100018","article-title":"An overview of anti-chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelope","volume":"1","author":"Chandley","year":"2023","journal-title":"Microbe"},{"key":"2025100302021585300_ref18","doi-asserted-by":"crossref","first-page":"taae123","DOI":"10.1093\/jtm\/taae123","article-title":"From bench to clinic: the development of VLA1553\/IXCHIQ, a live-attenuated chikungunya vaccine","volume":"31","author":"Chen","year":"2024","journal-title":"J Travel Med"},{"key":"2025100302021585300_ref19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/trstmh\/trac045","article-title":"Treatment of chikungunya-associated joint pain: a systematic review of controlled clinical trials","volume":"116","author":"Rodrigo","year":"2022","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2025100302021585300_ref20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/1806-9282.64.01.63","article-title":"Treatment of chikungunya chronic arthritis: a systematic review","volume":"64","author":"Sales","year":"2018","journal-title":"Rev Assoc Med Bras"},{"key":"2025100302021585300_ref21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/14787210.2018.1450629","article-title":"Treatment of chikungunya musculoskeletal disorders: a systematic review","volume":"16","author":"Guaraldo","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025100302021585300_ref22","doi-asserted-by":"crossref","first-page":"e0179028","DOI":"10.1371\/journal.pone.0179028","article-title":"Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: a systematic review","volume":"12","author":"Mart\u00ed-Carvajal","year":"2017","journal-title":"PloS One"},{"key":"2025100302021585300_ref23","doi-asserted-by":"crossref","first-page":"taae005","DOI":"10.1093\/jtm\/taae005","article-title":"Chikungunya infection in returned travellers: results from the GeoSentinel network, 2005\u20132020","volume":"31","author":"Bierbrier","year":"2024","journal-title":"J Travel Med"},{"key":"2025100302021585300_ref24","doi-asserted-by":"crossref","first-page":"taad060","DOI":"10.1093\/jtm\/taad060","article-title":"Impact, healthcare utilization and costs of travel-associated mosquito-borne diseases in international travellers: a prospective study","volume":"30","author":"Tozan","year":"2023","journal-title":"J Travel Med"},{"key":"2025100302021585300_ref25","doi-asserted-by":"crossref","first-page":"taad008","DOI":"10.1093\/jtm\/taad008","article-title":"Chikungunya: risks for travellers","volume":"30","author":"Simon","year":"2023","journal-title":"J Travel Med"},{"key":"2025100302021585300_ref26","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025100302021585300_ref27","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025100302021585300_ref28","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"2025100302021585300_ref29","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses [Internet]","author":"Wells","year":"2009"},{"key":"2025100302021585300_ref30","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ."},{"key":"2025100302021585300_ref31","volume-title":"RStudio: Integrated Development Environment for R. Version 2024.12.0+467","author":"RStudio Team","year":"2024"},{"key":"2025100302021585300_ref32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/RHU.0000000000000943","article-title":"Successful methotrexate treatment of chronic chikungunya arthritis","volume":"26","author":"Amaral","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2025100302021585300_ref33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4269\/ajtmh.23-0205","article-title":"Therapy for chikungunya arthritis: a study of 133 Brazilian patients","volume":"109","author":"Amaral","year":"2023","journal-title":"Am J Trop Med Hyg"},{"key":"2025100302021585300_ref34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/0115733971278715231208114037","article-title":"Chikungunya arthritis treatment with methotrexate and dexamethasone: a randomized, double-blind","volume":"20","author":"Amaral","year":"2024","journal-title":"Placebo-controlled Trial Curr Rheumatol Rev"},{"key":"2025100302021585300_ref35","first-page":"83","article-title":"Post-chikungunya chronic arthritis--our experience with DMARDs over two year follow up","volume":"59","author":"Ganu","year":"2011","journal-title":"J Assoc Physicians India"},{"key":"2025100302021585300_ref36","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s10067-016-3429-0","article-title":"Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study","volume":"36","author":"Ravindran","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025100302021585300_ref37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1573397115666190925154140","article-title":"Methotrexate in early chikungunya arthritis: a 6 month randomized controlled open-label trial","volume":"16","author":"Adarsh","year":"2020","journal-title":"Curr Rheumatol Rev"},{"key":"2025100302021585300_ref38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.38221","article-title":"Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection","volume":"66","author":"Chopra","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025100302021585300_ref39","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1177\/0973369820110103","article-title":"Clinical profile and long-term sequelae of chikungunya fever","volume":"6","author":"Paul","year":"2011","journal-title":"Indian J Rheumatol"},{"key":"2025100302021585300_ref40","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/infdis\/jiaa261","article-title":"Chikungunya-induced arthritis in Reunion Island: a long-term observational follow-up study showing frequently persistent joint symptoms, some cases of persistent chikungunya immunoglobulin M positivity, and no anticyclic citrullinated peptide seroconversion after 13 years","volume":"222","author":"Guillot","year":"2020","journal-title":"J Infect Dis"},{"key":"2025100302021585300_ref41","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jbspin.2009.08.005","article-title":"A report of 21 cases of rheumatoid arthritis following chikungunya fever. a mean follow-up of two years","volume":"76","author":"Bouquillard","year":"2009","journal-title":"Joint Bone Spine"},{"key":"2025100302021585300_ref42","doi-asserted-by":"crossref","first-page":"e0003603","DOI":"10.1371\/journal.pntd.0003603","article-title":"Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012","volume":"9","author":"Javelle","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2025100302021585300_ref43","doi-asserted-by":"crossref","first-page":"236","DOI":"10.33696\/immunology.6.211","article-title":"Development of a chikungunya arthritis disease activity score (CHIK-DAS) based on a prospective cohort study","volume":"6","author":"Chang","year":"2024","journal-title":"J Cell Immunol"},{"key":"2025100302021585300_ref44","doi-asserted-by":"crossref","first-page":"taad041","DOI":"10.1093\/jtm\/taad041","article-title":"Clinical evaluation of BioFire\u00ae multiplex-PCR panel for acute undifferentiated febrile illnesses in travellers: a prospective multicentre study","volume":"30","author":"Camprub\u00ed-Ferrer","year":"2023","journal-title":"J Travel Med"},{"key":"2025100302021585300_ref45","doi-asserted-by":"crossref","first-page":"taae064","DOI":"10.1093\/jtm\/taae064","article-title":"Novel chikungunya and dengue vaccines: travel medicine applications","volume":"31","author":"Steffen","year":"2024","journal-title":"J Travel Med"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taaf067\/63746001\/taaf067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/6\/taaf067\/63746001\/taaf067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/6\/taaf067\/63746001\/taaf067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:02:27Z","timestamp":1759471347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taaf067\/8199468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,14]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taaf067","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,14]]},"article-number":"taaf067"}}